Prelude reports Q3 2026 results, advances KAT6A and JAK2V617F programsNov 16Quarterly updateLeonaBioPrelude Therapeutics Incorporated
LeonaBio reports Q2 2026 results, enrollment nears completion for ELAINE-3 trialAug 14Quarterly updateLeonaBio